Inclusion Criteria:  Have been diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 1 year prior to screening Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²) Be treated for T2DM with stable dose of metformin, a stable dose of a dipeptidyl peptidase-4 (DPP-4) inhibitor with or without metformin, or a stable dose of a glucagon-like peptide-1 (GLP-1) receptor agonist with or without metformin for at least 3 months prior to screening  Exclusion Criteria:  Have an abnormality in the 12-lead ECG Have a supine blood pressure at screening Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5x upper limit of normal (ULN) Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (except T2DM and controlled thyroid disease), haematological, or neurological disorders Are receiving chronic (lasting longer than 14 consecutive days) systemic or inhaled glucocorticoid therapy Have an average weekly alcohol intake